Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Ad26.ZEBOV

8 clinical trials

4 indications

Indication
Hemorrhagic Fever
Indication
Ebola
Indication
Healthy
Indication
HIV
Clinical trial
A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Status: Terminated, Estimated PCD: 2021-12-13
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, Reactogenicity, and Consistency of a Heterologous 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN®-Filo in Adult Participants
Status: Completed, Estimated PCD: 2022-04-25
Clinical trial
A Phase 3 Open-label Randomized Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women
Status: Completed, Estimated PCD: 2023-03-02
Clinical trial
A Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV and MVA-BN®-Filo in Infants Aged 4-11 Months in Guinea and Sierra Leone
Status: Completed, Estimated PCD: 2022-08-22
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate A Range of Dose Levels of a Heterologous Prime-Boost Regimen of Ad26.ZEBOV and MVA-BN®-Filo in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2016-06-07
Clinical trial
Partnership for Research on Ebola VACcinations (PREVAC)
Status: Active (not recruiting), Estimated PCD: 2019-12-24
Clinical trial
An Open Label Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Children Previously Vaccinated With the Ad26.ZEBOV and MVA-BN-Filo Vaccine Regimen
Status: Completed, Estimated PCD: 2021-09-17
Clinical trial
An Open Label, Phase 2 Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Human Immunodeficiency Virus Positive (HIV+) Adults Previously Vaccinated With the Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen
Status: Completed, Estimated PCD: 2021-11-17